Moderna Inc MRNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
The excitement around Moderna's cancer vaccine is cooling. Here's why.
-
Moderna's cancer vaccine is 'likely' to get approved. Skeptics question if it will be the best option.
-
The stock market is splitting in two. Is that signaling trouble ahead, or just a new set of winners?
-
Moderna's cancer vaccine hits its targets, but a data leak rattled investors and the stock tumbled
-
Moderna has a plan to revolutionize how certain cancers are treated. We're about to find out its potential in melanoma.
-
7 healthcare stocks that stand out as investors pay up for the sector
-
7 healthcare stocks that stand out as -2-
-
Flu season is already here. Here's what to know about this year's flu shots.
Trading Information
- Previous Close Price
- €175.80
- Day Range
- €183.34–193.36
- 52-Week Range
- €19.48–220.90
- Bid/Ask
- €0.00 / €0.00
- Shares Outstanding
- 399.24M
- Market Cap
- €77.20B
- Volume/Avg
- 59 / 788
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 40.16
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 4,700
- Website
- https://www.modernatx.com
Competitors
Valuation
|
Metric
|
MRNA
|
BNTX
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 9.77 |
Price/Book Value | 13.03 | 1.08 | 1.99 |
Price/Sales | 40.16 | 6.98 | 2.68 |
Price/Cash Flow | — | — | 11.08 |
Price/Earnings
MRNA
BNTX
PFE
Financial Strength
|
Metric
|
MRNA
|
BNTX
|
PFE
|
|---|---|---|---|
Quick Ratio | 2.08 | 7.71 | 0.85 |
Current Ratio | 2.29 | 7.85 | 1.27 |
Interest Coverage | −79.21 | — | 2.36 |
Quick Ratio
MRNA
BNTX
PFE
Profitability
|
Metric
|
MRNA
|
BNTX
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | −23.64% | −5.73% | 8.46% |
Return on Equity (Normalized) | −33.54% | −6.58% | 19.70% |
Return on Invested Capital (Normalized) | −31.72% | −6.97% | 12.66% |
Return on Assets
MRNA
BNTX
PFE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&&^>G# | LOCK|^@NgX | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>@hJzc^ | LOCK|Tx#T | $84B | |||
| Moderna Inc
MRNA
| LOCK|fzP>x% | LOCK|k$ | $83B | |||
| argenx SE ADR
ARGX
| LOCK|LFhVBR | LOCK|^n | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|DdkpTFv | LOCK|Ngc | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%%<!?! | LOCK|LSt^s | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>J@B#W&@ | LOCK|Dfkn | $29B | |||
| Incyte Corp
INCY
| LOCK|l&%G%G | LOCK|^HL | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|qXM<!m< | LOCK|x! | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|b>$LGk | LOCK|#d | $14B |
United States